Interventional Strategies in Cancer-induced Cardiovascular Disease.
Current oncology reports
PURPOSE OF REVIEW: To highlight the range of illnesses and procedures that the interventional onco-cardiologists face in their daily practice, along with the recent additions to anti-cancer therapies and their related cardiotoxicity.
RECENT FINDINGS: Immune checkpoint inhibitors (ICI) are not devoid of cardiotoxicity as thought earlier and lead to an increased incidence of myocarditis. Transcatheter valve replacement has been shown to be a safer alternative to surgical replacement in cancer patients. Interventional onco-cardiology is a novel field that addresses cardiovascular diseases in the setting of cancer. Traditionally excluding cancer patients from clinical trials has led to a dearth of information needed to tackle cardiac conditions like Takotsubo cardiomyopathy, malignant pericardial effusions, and radiation-induced vascular diseases encountered either exclusively or predominantly in this high-risk population. This review discusses the various treatment options available in the interventional armamentarium with a particular focus on ICI-myocarditis and transcatheter aortic valve replacement in cancer patients.
Pushparaji B, Donisan T, Balanescu DV, Palaskas N, Kim P, Lopez-Mattei J, Cilingiroglu M, Hassan SA, Boudoulas KD, Marmagkiolis K, Hajjar LA, Iliescu CA. Interventional Strategies in Cancer-induced Cardiovascular Disease. Curr Oncol Rep. 2021 Sep 27;23(11):133. doi: 10.1007/s11912-021-01113-y. PMID: 34570291.